Publications
High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort University of Antwerp
Prognosis and treatment of FOLFOX therapy related interstitial pneumonia : a plea for multimodal immune modulating therapy in the respiratory insufficient patient Ghent University University of Antwerp
Developing nanobodies to advance immune checkpoint therapy that targets lymphocyteactivation gene 3 Vrije Universiteit Brussel
example, inhibitory immune checkpoints (ICPs) are imperative to control and limit
T-cell activation and functionality. These control mechanisms can prevent excessive inflammation, tissue damage and ultimately autoimmunity. Unfortunately, cancer cells exploit ICPs to generate additional defense mechanisms against the host’s immune system. Upregulation of ...
Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy Institute of Tropical Medicine
The immune mechanisms of lung parenchymal damage in tuberculosis and the role of host-directed therapy Institute of Tropical Medicine
Impaired lung function is common in people with a history of tuberculosis. Host-directed therapy added to tuberculosis treatment may reduce lung damage and result in improved lung function. An understanding of the pathogenesis of pulmonary damage in TB is fundamental to successfully predicting which interventions could be beneficial. In this review, we describe the different features of TB immunopathology that lead to impaired lung function, ...
Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma Vrije Universiteit Brussel
BACKGROUND: Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the present case report.
CASE: We report a patient with ACTH-secreting pituitary carcinoma, progressive after multiple lines of therapy including ...
Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model Vrije Universiteit Brussel
Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 represents a new and growing type of cancer therapy. We studied immunological changes in response to TRT with Lutetium-177 labeled anti-human CD20 camelid single domain antibodies (sdAbs) in a B16-melanoma model transfected to express human CD20, the target antigen, and ovalbumin, a surrogate tumor antigen. High-dose TRT induced melanoma cell death, calreticulin ...